MetaCap

CorMedix (CRMD) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ovid Therapeutics (OVID) has outperformed CorMedix (CRMD) over the past year, gaining 57.1% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -32.5% for OVID. CorMedix is the larger company by market cap ($419.2 million vs $415.2 million), about 1.0 times the size, while Ovid Therapeutics is growing revenue faster (+1181.3% vs +617.0%).

CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -240.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRMD-45.56%OVID+57.14%
+120%+29%-62%
Nov 21, 20251 yearNov 20, 2026
CRMD+2.73%OVID-36.05%
+203%+48%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRMD versus OVID key metrics
MetricCRMDOVID
Share price$5.27$2.20
Market cap$419.16M$415.21M
1-day change+3.74%-5.98%
YTD return-54.69%+34.97%
1-year return-45.56%+57.14%
5-year return+3.94%-32.52%
P/E ratio (TTM)8.23—
Forward P/E15.06—
EPS (TTM)$0.64$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$311.71M$7.25M
Revenue growth (YoY)+617.03%+1181.27%
Net income (latest FY)$163.06M$-17.41M
Gross margin88.46%—
Operating margin48.17%-585.20%
Net margin52.31%-240.13%
52-week high$13.02$3.11
52-week low$4.47$1.26
Distance from 52-week high-59.52%-29.15%
Analyst consensusbuystrong_buy
Avg. price target upside+161.86%+179.55%
Average volume1.44M1.98M
Shares outstanding79.54M188.73M
Employees19123
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OVID has outperformed CRMD by 102.7 percentage points over the past year.
  • CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
  • Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +617.03%).

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

CRMD vs OVID FAQ

Which is bigger, CorMedix or Ovid Therapeutics?

CorMedix (CRMD) is larger, with a market capitalization of $419.16M compared with $415.21M for Ovid Therapeutics (OVID).

Which stock has performed better over the past year, CRMD or OVID?

OVID returned +57.14% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.

Are CorMedix and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons